ArticleMaedica2025
Impact of the COVID-19 Pandemic on Brain Metastases in Breast Cancer Patients.
Article in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the impact of the COVID-19 pandemic on the diagnosis and treatment delays of brain metastases secondary to breast cancer, and to compare patient demographics, disease characteristics and outcomes before and during the pandemic. Materials and methods: A retrospective study was conducted on 100 patients who were surgically treated for brain metastases in the Neurosurgery Clinic of "Prof. Dr. Nicolae Oblu" Clinical Emergency Hospital, Iasi, Romania. Patients were divided into two groups: pre-pandemic (2018-2020, n=57) and pandemic (2020-2022, n=43). Clinicopathological data, including demographics, metastasis localization, number and duration, were collected and analyzed. Results: The pandemic period saw a shift towards younger patients, with 51% younger than 55 years compared to an average age of 57.9 years before the pandemic. Metastases were mostly located in the parietal lobe (61%). Despite a balanced rural-urban patient distribution, diagnostic delays were observed, with an average metastasis duration of 17 months. Patients from rural areas and older subjects showed tendencies towards later diagnosis. The number of metastases varied, with nearly half presenting a single lesion. Conclusions: COVID-19 pandemic-related disruptions in healthcare services led to delayed diagnosis and treatment of brain metastases, particularly impacting older and rural patients. These findings underscore the need for improved healthcare resilience and equitable access to oncological care to minimize delays and optimize outcomes during public health emergencies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.